gilead sciences inc recorded a small boost in secondquarter revenue exceeding wall street expectations as demand for its hiv and oncology treatments offset decreased sales for its covid19 treatment and other therapies the biopharmaceutical companys net profit for the period was 114 billion or 91 cents a share compared with 152 billion or 121 a share a year ago adjusted earnings were 158 a share analysts polled by factset had expected adjusted earnings per share of 159 gileads profit decline was from higher acquired inprocess research and development expenses from an upfront payment of 300 million related to the dragonfly therapeutics inc collaboration plus higher net unrealized losses from its strategic equity investments total revenue increased 1 to 63 billion analysts had estimated 586 billion in revenue the company said the slight revenue gain was primarily due to increased sales in hiv and oncology products offset partially by decreased sales of veklury and hepatitis c virus products sales of gileads flagship hiv therapy biktarvy rose 28 to 26 billion in the quarter sales of descovy rose 6 in the quarter veklury sales fell by 46 to 445 million for the second quarter which the company said reflects rates for covid19 and severity of infections and hospitalizations as well as the availability uptake and effectiveness of vaccinations